# Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer

> **NCT04947189** · PHASE1,PHASE2 · RECRUITING · sponsor: **St Vincent's Hospital, Sydney** · enrollment: 65 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Seviteronel-D (Seivteronel in combination with dexamethasone)
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04947189
- **Lead sponsor:** St Vincent's Hospital, Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-07
- **Final completion:** 2027-12
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04947189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04947189, "Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04947189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*